Recruiting
Phase 2
Phase 3

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Sponsor:

Kartos Therapeutics, Inc.

Code:

NCT03662126

Conditions

Primary Myelofibrosis (PMF)

Post-Polycythemia Vera MF (Post-PV-MF)

Post-Essential Thrombocythemia MF (Post-ET-MF)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

KRT-232

Best Available Therapy (BAT)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information